Interview made by Didier Testot, journalist, on the Web TV www.labourseetlavie.com
Overview of DBV Technologies initial public offering on NYSE Euronext market
Along with DBV Technologies initial public offering, Pierre-Henri Benhamou presents his company developing desensitization patches
Interview with Pierre-Henri Benhamou, CEO of DBV Technologies
Animation explaining how DBV uses the Epicutaenous Immunotherapy, with its VIASKIN patch to desensitize allergic patients